SCHEMBL6860723

SCHEMBL6860723

CCCCOC(=O)N1CCCC1S

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.45
LMNA P02545 1/20 0.45
POLB P06746 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.44
GBA2 Q9HCG7 1/20 0.42
RAB9A P51151 1/20 0.39
ALDH1A1 P00352 3/20 0.39
ATM Q13315 1/20 0.37
HPGD P15428 3/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
DPP4 P27487 2/20 0.36
FAP Q12884 1/20 0.36
DPP8 Q6V1X1 1/20 0.36
DPP9 Q86TI2 1/20 0.36
DPP7 Q9UHL4 1/20 0.36
ECE1 P42892 1/20 0.36
FKBP1A P62942 1/20 0.36
ACE P12821 1/20 0.35
ACE2 Q9BYF1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4202768 0.83 POLB (0.46) SMN1; SMN2LMNAPOLBL3MBTL1GBA2
SCHEMBL2731646 0.83 POLB (0.46) SMN1; SMN2LMNAPOLBL3MBTL1GBA2
SCHEMBL14144107 0.81 POLB (0.45) SMN1; SMN2LMNAPOLBL3MBTL1GBA2
SCHEMBL27971973 0.81 POLB (0.45) SMN1; SMN2LMNAPOLBL3MBTL1GBA2
SCHEMBL2634067 0.80 RAB9A (0.62) SMN1; SMN2LMNAL3MBTL1RAB9AALDH1A1
SCHEMBL6207733 0.80 POLB (0.53) SMN1; SMN2LMNAPOLBL3MBTL1GBA2
SCHEMBL2723323 0.80 LMNA (0.44) SMN1; SMN2LMNAPOLBL3MBTL1GBA2
SCHEMBL5250880 0.80 POLB (0.44) SMN1; SMN2LMNAPOLBL3MBTL1GBA2
SCHEMBL695608 0.80 RAB9A (0.62) SMN1; SMN2LMNAL3MBTL1RAB9AALDH1A1
SCHEMBL1982237 0.80 POLB (0.53) SMN1; SMN2LMNAPOLBL3MBTL1GBA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6790860-B2 USEFUL AS INHIBITORS OF METALLOPROTEASES, E.G. ZINC PROTEASES; EFFECTIVE IN TREATING DISEASE STATES ASSOCIATED WITH VASOCONSTRICTION HOFFMANN-LA ROCHE INC. 2004-09-14 US disclosed